1460. Respiratory Syncytial Virus (RSV)-Related Clinical Events among a Medicare-Insured Population in the United States. (15th December 2022)

• Record Type: Journal Article
• Authors: DeMartino, Jessica K K; Lafeuille, Marie-Hélène; Emond, Bruno; Rossi, Carmine; Wang, Jingru; Liu, Stephanie; Lefebvre, Patrick; Krishnarajah, Girishanthy
• Is Part Of: Open forum infectious diseases. Volume 9:(2022)Supplement 2
• Publication Date: 2022-12-15
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac492.1287
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: RSV is a contagious pathogen that is often underrecognized in older adults. While the general burden of RSV has previously been assessed, little is known on the frequency and factors associated with RSV-related clinical events in older adults. Methods: Patients ≥60 years old with a diagnosis code for RSV (index date) and ≥6 months of enrollment pre-index (baseline) were analyzed using claims data from the 100% Medicare database (2007-2019). The following RSV-related clinical events were assessed during the up-to-6-month post-index period: acute respiratory failure, chronic respiratory disease (asthma or chronic obstructive pulmonary disease), congestive heart failure, dyspnea, hypoxia, non-RSV lower/upper respiratory tract infection, and pneumonia. Patients were at risk of developing each clinical event if they did not already have the event at baseline. A stepwise Poisson regression model was used to identify baseline predictors of having ≥1 clinical event. Results: A total of 175, 392 patients were included (mean age: 79.0 years, 64.8% female, 78.4% white, 76.9% had ≥1 RSV-related clinical event at baseline). During the up-to-6-month period following RSV infection, 47.9% had ≥1 incident RSV-related clinical event (Figure ). The mean (median) time to a clinical event was 1.0 (0.1) month. Having an event was more likely for patients with baseline conditions (coronary artery disease, diabetes, or one of the above RSV-related clinical events [except pneumonia and asthma]) or with chemotherapy, chest x-ray, organ transplant, anti-asthmatic use, or bronchodilator use at baseline (incidence rate ratio [IRR] range=1.06 [bronchodilators] to 1.80 [chest x-ray], all P < .05); having an event was less likely for patients with one of the following: lower age, female gender, baseline influenza or RSV test, baseline use of antibiotics, or baseline use of influenza agents (IRR range=0.63 [antibiotics] to 0.92 [baseline RSV test], all P < .05). Figure RSV-related clinical events among Medicare beneficiaries ≥60 years old Conclusion: Almost half of patients ≥60 years old had an RSV-related clinical event within 1 month of RSV infection; patients with pre-existing conditions (≥75% of patients) were at higher risk of an event. These findings highlight that many older adults with RSV experience significant clinical events that burden both the patient and the healthcare system. Disclosures: Jessica K. K. DeMartino, PhD, Janssen Scientific Affairs, LLC: Employee of Janssen Scientific Affairs, LLC Marie-Hélène Lafeuille, MSc, Janssen Scientific Affairs, LLC: Advisor/Consultant Bruno Emond, MSc, Janssen Scientific Affairs, LLC: Advisor/Consultant Carmine Rossi, PhD, Janssen Scientific Affairs, LLC: Advisor/Consultant Jingru Wang, BA, Janssen Scientific Affairs, LLC: Advisor/Consultant Stephanie Liu, MS, Janssen Scientific Affairs, LLC: Advisor/Consultant Patrick Lefebvre, MSc, Janssen Scientific Affairs, LLC: Advisor/Consultant Girishanthy Krishnarajah, MBA, Janssen Scientific Affairs, LLC: Employee of Janssen Scientific Affairs, LLC.